Joel Greenblatt's TGTX Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 45,332 shares of TG Therapeutics, Inc. (TGTX) worth $1.64 M, representing 0.01% of the portfolio. First purchased in 2019-Q3, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in TGTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2022, adding 115,686 shares. Largest reduction occurred in Q4 2024, reducing 64,333 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's TG Therapeutics (TGTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly TG Therapeutics (TGTX) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2019 | +11,105 | New Buy | 11,105 | $5.58 |
| Q4 2019 | -11,105 | Sold Out | 11,105 | $0.00 |
| Q2 2020 | +44,788 | New Buy | 44,788 | $19.47 |
| Q3 2020 | -11,088 | Reduce 24.76% | 33,700 | $26.77 |
| Q4 2020 | +16 | Add 0.05% | 33,716 | $52.02 |
| Q1 2021 | -22,960 | Reduce 68.10% | 10,756 | $48.16 |
| Q2 2021 | -10,756 | Sold Out | 10,756 | $0.00 |
| Q4 2022 | +126,442 | New Buy | 126,442 | $11.83 |
| Q1 2023 | -5,555 | Reduce 4.39% | 120,887 | $15.04 |
| Q2 2023 | +9,807 | Add 8.11% | 130,694 | $24.84 |
| Q3 2023 | -59,271 | Reduce 45.35% | 71,423 | $8.36 |
| Q4 2023 | +24,827 | Add 34.76% | 96,250 | $17.08 |
| Q1 2024 | -24,674 | Reduce 25.64% | 71,576 | $15.21 |
| Q2 2024 | +1,731 | Add 2.42% | 73,307 | $17.79 |
| Q3 2024 | +41,975 | Add 57.26% | 115,282 | $23.39 |
| Q4 2024 | -64,333 | Reduce 55.80% | 50,949 | $30.10 |
| Q1 2025 | -4,214 | Reduce 8.27% | 46,735 | $39.43 |
| Q2 2025 | -1,403 | Reduce 3.00% | 45,332 | $35.99 |
Joel Greenblatt's TG Therapeutics Investment FAQs
Joel Greenblatt first purchased TG Therapeutics, Inc. (TGTX) in Q3 2019, acquiring 11,105 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held TG Therapeutics, Inc. (TGTX) for 25 quarters since Q3 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to TG Therapeutics, Inc. (TGTX) was in Q4 2022, adding 126,442 shares worth $1.5 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 45,332 shares of TG Therapeutics, Inc. (TGTX), valued at approximately $1.64 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, TG Therapeutics, Inc. (TGTX) represents approximately 0.01% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in TG Therapeutics, Inc. (TGTX) was 130,694 shares, as reported at the end of Q2 2023. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.